EA201391329A1 - Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) - Google Patents

Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)

Info

Publication number
EA201391329A1
EA201391329A1 EA201391329A EA201391329A EA201391329A1 EA 201391329 A1 EA201391329 A1 EA 201391329A1 EA 201391329 A EA201391329 A EA 201391329A EA 201391329 A EA201391329 A EA 201391329A EA 201391329 A1 EA201391329 A1 EA 201391329A1
Authority
EA
Eurasian Patent Office
Prior art keywords
expression
activator
transcription
modulation
signal transducer
Prior art date
Application number
EA201391329A
Other languages
English (en)
Other versions
EA029317B1 (ru
Inventor
Эрик И. Суэйзи
Сьюзан М. Фрейер
Роберт А. Маклеод
Янсу Ким
Original Assignee
Айсис Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Айсис Фармасьютикалс, Инк. filed Critical Айсис Фармасьютикалс, Инк.
Publication of EA201391329A1 publication Critical patent/EA201391329A1/ru
Publication of EA029317B1 publication Critical patent/EA029317B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Abstract

В изобретении раскрыты антисмысловые соединения и способы снижения экспрессии мРНК и белка STAT3. Такие способы, соединения и композиции являются полезными для лечения, предупреждения или облегчения гиперпролиферативных заболеваний.
EA201391329A 2011-04-01 2012-03-30 Одноцепочечный антисмысловой модифицированный олигонуклеотид для ингибирования экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) и его применение для лечения гиперпролиферативного заболевания EA029317B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161471035P 2011-04-01 2011-04-01
US201161471045P 2011-04-01 2011-04-01
US201161471001P 2011-04-01 2011-04-01
US201161471015P 2011-04-01 2011-04-01
US201161558316P 2011-11-10 2011-11-10
US201161558308P 2011-11-10 2011-11-10
PCT/US2012/031642 WO2012135736A2 (en) 2011-04-01 2012-03-30 Modulation of signal transducer and activator of transcription 3 (stat3) expression

Publications (2)

Publication Number Publication Date
EA201391329A1 true EA201391329A1 (ru) 2014-07-30
EA029317B1 EA029317B1 (ru) 2018-03-30

Family

ID=46932413

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201391329A EA029317B1 (ru) 2011-04-01 2012-03-30 Одноцепочечный антисмысловой модифицированный олигонуклеотид для ингибирования экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3) и его применение для лечения гиперпролиферативного заболевания
EA201792185A EA201792185A3 (ru) 2011-04-01 2012-03-30 Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201792185A EA201792185A3 (ru) 2011-04-01 2012-03-30 Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)

Country Status (33)

Country Link
US (4) US8816056B2 (ru)
EP (2) EP3466960A3 (ru)
JP (1) JP5943993B2 (ru)
KR (2) KR20190092590A (ru)
CN (2) CN107012144A (ru)
AU (1) AU2012236206C1 (ru)
BR (1) BR112013024768B1 (ru)
CA (1) CA2831915C (ru)
CL (1) CL2013002773A1 (ru)
CO (1) CO6821885A2 (ru)
CY (1) CY1121460T1 (ru)
DK (1) DK2697243T3 (ru)
DO (1) DOP2013000216A (ru)
EA (2) EA029317B1 (ru)
EC (1) ECSP13012909A (ru)
ES (1) ES2709495T3 (ru)
GT (1) GT201300232A (ru)
HR (1) HRP20182169T1 (ru)
HU (1) HUE042173T2 (ru)
IL (2) IL228569A (ru)
LT (1) LT2697243T (ru)
ME (1) ME03317B (ru)
MX (1) MX340086B (ru)
MY (1) MY163004A (ru)
NI (1) NI201300101A (ru)
PE (2) PE20142463A1 (ru)
PL (1) PL2697243T3 (ru)
PT (1) PT2697243T (ru)
RS (1) RS58489B1 (ru)
SG (1) SG193504A1 (ru)
SI (1) SI2697243T1 (ru)
WO (1) WO2012135736A2 (ru)
ZA (1) ZA201308153B (ru)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE042173T2 (hu) 2011-04-01 2019-06-28 Ionis Pharmaceuticals Inc 'Signal transducer and activator of transcription 3' (stat3) expresszió modulálása
EP2831278B1 (en) 2012-03-28 2019-05-08 Somalogic, Inc. Aptamers to pdgf and vegf and their use in treating pdgf and vegf mediated conditions
JP6570447B2 (ja) * 2012-10-15 2019-09-04 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｃ９ｏｒｆ７２発現を調節するための組成物
WO2014062736A1 (en) 2012-10-15 2014-04-24 Isis Pharmaceuticals, Inc. Methods for monitoring c9orf72 expression
EP3483273A1 (en) 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
IL284593B2 (en) 2013-05-01 2023-02-01 Ionis Pharmaceuticals Inc Compositions and methods for modulation of hbv and ttr expression
CN105452461B (zh) * 2013-07-02 2021-04-13 Ionis制药公司 生长激素受体的调节剂
EP3044334B1 (en) 2013-09-09 2020-08-12 Somalogic, Inc. Pdgf and vegf aptamers having improved stability and their use in treating pdgf and vegf mediated diseases and disorders
AU2014331652B2 (en) 2013-10-11 2020-05-21 Ionis Pharmaceuticals, Inc. Compositions for modulating C9ORF72 expression
EP3137605B1 (en) 2014-05-01 2020-10-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating angiopoietin-like 3 expression
RU2724527C2 (ru) 2014-05-01 2020-06-23 Ионис Фармасьютикалз, Инк. Композиции и способы модулирования экспрессии рецептора гормона роста
BR112016022593B1 (pt) 2014-05-01 2022-04-26 Ionis Pharmaceuticals, Inc Compostos oligoméricos, composições que os compreendem, e usos dos mesmos
US10570169B2 (en) 2014-05-22 2020-02-25 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
EP3189141B1 (en) * 2014-09-02 2020-06-24 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Antisense oligonucleotides targeting 3'utr region of a20
WO2016062722A1 (en) 2014-10-24 2016-04-28 Astrazeneca Ab Combination
SG11201708468YA (en) 2015-04-16 2017-11-29 Ionis Pharmaceuticals Inc Compositions for modulating c9orf72 expression
EP3316894A4 (en) 2015-07-02 2019-06-19 City of Hope COMPOUNDS AND COMPOSITIONS USING PHOSPHOROIDED OLIGODESOXYNUCLEOTIDE AND METHOD OF USE THEREOF
PE20180800A1 (es) 2015-07-10 2018-05-09 Ionis Pharmaceuticals Inc Moduladores de diaciglicerol aciltransferasa 2 (dgat2)
WO2017079291A1 (en) 2015-11-02 2017-05-11 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating c90rf72
WO2017078099A1 (ja) 2015-11-06 2017-05-11 東レ株式会社 癌の治療及び／又は予防用医薬組成物
WO2017079739A1 (en) 2015-11-06 2017-05-11 Ionis Pharmaceuticals, Inc. MODULATING APOLIPOPROTEIN (a) EXPRESSION
SG10201913477UA (en) 2016-04-29 2020-02-27 Univ Nanyang Tech G-quadruplex-containing antisense oligonucleotides
CN105985961B (zh) * 2016-07-22 2019-01-29 广西师范大学 抑制EGFR基因表达的siRNA及其应用
KR20190065341A (ko) 2016-10-06 2019-06-11 아이오니스 파마수티컬즈, 인코포레이티드 올리고머 화합물들의 접합 방법
AU2017368050A1 (en) 2016-11-29 2019-06-20 Puretech Lyt, Inc. Exosomes for delivery of therapeutic agents
IL269608B1 (en) * 2017-04-19 2024-02-01 Bio Path Holdings Inc Compounds Containing Phosphorus-Ethoxy-Based Nucleic Acids for STAT3 Inhibition for Use in the Treatment of Cancer and Autoimmune Diseases
GB2574793B (en) * 2018-05-01 2022-09-28 Flexenable Ltd Organic liquid crystal display device with one or more oxygen permeable films
TW202023573A (zh) * 2018-09-19 2020-07-01 美商Ionis製藥公司 Pnpla3表現之調節劑
CA3147366A1 (en) * 2019-08-14 2021-02-18 Adam T. BOUTIN Extracellular vesicles with stat3-antisense oligonucleotides
US20220354880A1 (en) 2019-09-30 2022-11-10 Astrazeneca Ab Combination treatment for cancer
US20220275374A1 (en) * 2019-11-14 2022-09-01 The Board Of Regents Of The University Of Oklahoma Oligonucleotide interference treatments of prostate cancer
CN114908094B (zh) * 2022-05-31 2024-03-12 中山大学 一类反义寡核苷酸分子及其在制备治疗恶性肿瘤药物中的应用
WO2024003241A1 (en) 2022-06-30 2024-01-04 Astrazeneca Ab Treatment for immuno-oncology resistant subjects with an anti pd-l1 antibody an antisense targeted to stat3 and an inhibitor of ctla-4

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2699808A (en) 1944-10-06 1955-01-18 Mark W Lowe Apparatus for peeling tomatoes
US2699508A (en) 1951-12-21 1955-01-11 Selectronics Inc Method of mounting and construction of mounting for low frequency piezoelectric crystals
US6582908B2 (en) 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
AU2580892A (en) 1991-09-05 1993-04-05 Isis Pharmaceuticals, Inc. Determination of oligonucleotides for therapeutics, diagnostics and research reagents
JPH08504559A (ja) 1992-12-14 1996-05-14 ハネウエル・インコーポレーテッド 個別に制御される冗長巻線を有するモータシステム
US5801154A (en) 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
EP0676469A3 (en) 1994-04-04 1998-03-25 Tadamitsu Kishimoto Transcription Factor APRF
JPH10510981A (ja) 1994-05-16 1998-10-27 ブリガム アンド ウィメンズ ホスピタル ヌクレオチド配列を特性決定するための方法、装置及び組成物
EP0717110A1 (en) 1994-11-22 1996-06-19 Association Francaise Contre Les Myopathies LGMD gene
US5877021A (en) 1995-07-07 1999-03-02 Ribozyme Pharmaceuticals, Inc. B7-1 targeted ribozymes
US5656408A (en) 1996-04-29 1997-08-12 Xerox Corporation Coated carrier particles
DE69735820T2 (de) 1997-01-10 2006-12-21 Kishimoto, Tadamitsu, Tondabayashi Neues protein, welches die funktion von stat reguliert
US6770748B2 (en) 1997-03-07 2004-08-03 Takeshi Imanishi Bicyclonucleoside and oligonucleotide analogue
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
US6794499B2 (en) 1997-09-12 2004-09-21 Exiqon A/S Oligonucleotide analogues
CN1273476C (zh) 1997-09-12 2006-09-06 埃克西康有限公司 寡核苷酸类似物
US20030228597A1 (en) 1998-04-13 2003-12-11 Cowsert Lex M. Identification of genetic targets for modulation by oligonucleotides and generation of oligonucleotides for gene modulation
US7098192B2 (en) * 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6159694A (en) 1999-04-08 2000-12-12 Isis Pharmaceuticals Inc. Antisense modulation of stat3 expression
NZ514348A (en) 1999-05-04 2004-05-28 Exiqon As L-ribo-LNA analogues
US6525191B1 (en) 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
JP2003504048A (ja) 1999-07-09 2003-02-04 ユニベルシテ ドゥ リエージュ 低温活性ベータ・ガラクトシダーゼ、その製法、及びその使用
US6248586B1 (en) 1999-12-17 2001-06-19 Isis Pharmaceuticals, Inc. Antisense modulation of PKA catalytic subunit C-alpha expression
WO2002092069A1 (en) 2001-05-11 2002-11-21 Elan Corporation, Plc Permeation enhancers
US20050196781A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA)
CA2452458A1 (en) 2001-07-03 2003-01-16 Isis Pharmaceuticals, Inc. Nuclease resistant chimeric oligonucleotides
JP2005516586A (ja) 2001-07-20 2005-06-09 ボード オブ トラスティーズ オブ ザ ユニヴァースティ オブ イリノイ 癌の処置に対する遺伝子標的を同定するための試薬および方法
US7259150B2 (en) * 2001-08-07 2007-08-21 Isis Pharmaceuticals, Inc. Modulation of apolipoprotein (a) expression
EP1562971B1 (en) 2002-11-05 2014-02-12 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
AU2003290598A1 (en) 2002-11-05 2004-06-03 Isis Pharmaceuticals, Inc. Modified oligonucleotides for use in rna interference
EP2314691A3 (en) 2002-11-14 2012-01-18 Dharmacon, Inc. Fuctional and hyperfunctional siRNA
WO2004106356A1 (en) 2003-05-27 2004-12-09 Syddansk Universitet Functionalized nucleotide derivatives
DK1661905T3 (da) 2003-08-28 2012-07-23 Takeshi Imanishi Hidtil ukendte syntetiske nukleinsyrer af N-O-krydsbindingstype
JP5379347B2 (ja) 2003-09-18 2013-12-25 アイシス ファーマシューティカルズ， インコーポレーテッド ４’−チオヌクレオシドおよびオリゴマー化合物
CN100357436C (zh) * 2005-07-01 2007-12-26 中国人民解放军第三军医大学 抑制Stat3基因表达的siRNA及其制备方法
CN1733916A (zh) * 2005-07-01 2006-02-15 中国人民解放军第三军医大学 抑制Stat3基因表达的siRNA及其制备方法
PL2314594T3 (pl) 2006-01-27 2014-12-31 Isis Pharmaceuticals Inc Zmodyfikowane w pozycji 6 analogi bicykliczne kwasów nukleinowych
DK2066684T3 (da) 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5´-Modificerede bicycliske nukleinsyreanaloge
US20100190837A1 (en) 2007-02-15 2010-07-29 Isis Pharmaceuticals, Inc. 5'-Substituted-2-F' Modified Nucleosides and Oligomeric Compounds Prepared Therefrom
US20100105134A1 (en) 2007-03-02 2010-04-29 Mdrna, Inc. Nucleic acid compounds for inhibiting gene expression and uses thereof
WO2008109494A1 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting stat3 gene expression and uses thereof
ES2388590T3 (es) 2007-05-30 2012-10-16 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos con puente aminometileno N-sustituido.
ES2386492T3 (es) 2007-06-08 2012-08-21 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos carbocíclicos
ES2376507T5 (es) 2007-07-05 2015-08-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos 6-disustituidos
EP2190994A2 (en) 2007-09-17 2010-06-02 Intradigm Corporation Compositions comprising stat3 sirna and methods of use thereof
AT507215B1 (de) 2009-01-14 2010-03-15 Boehler Edelstahl Gmbh & Co Kg Verschleissbeständiger werkstoff
HUE042173T2 (hu) 2011-04-01 2019-06-28 Ionis Pharmaceuticals Inc 'Signal transducer and activator of transcription 3' (stat3) expresszió modulálása
US9984408B1 (en) 2012-05-30 2018-05-29 Amazon Technologies, Inc. Method, medium, and system for live video cooperative shopping
EP3483273A1 (en) 2012-10-31 2019-05-15 Ionis Pharmaceuticals, Inc. Cancer treatment
US9778708B1 (en) 2016-07-18 2017-10-03 Lenovo Enterprise Solutions (Singapore) Pte. Ltd. Dual sided latching retainer for computer modules

Also Published As

Publication number Publication date
KR20140027205A (ko) 2014-03-06
US8816056B2 (en) 2014-08-26
PL2697243T3 (pl) 2019-05-31
ECSP13012909A (es) 2013-12-31
US10479993B2 (en) 2019-11-19
IL255858A (en) 2018-01-31
KR20190092590A (ko) 2019-08-07
SI2697243T1 (sl) 2019-05-31
IL228569A0 (en) 2013-12-31
MX340086B (es) 2016-06-24
BR112013024768A2 (pt) 2018-06-05
RS58489B1 (sr) 2019-04-30
PE20181518A1 (es) 2018-09-21
EP3466960A3 (en) 2019-04-24
CA2831915C (en) 2021-01-12
PT2697243T (pt) 2019-01-29
AU2012236206A1 (en) 2013-05-02
US9359608B2 (en) 2016-06-07
EA029317B1 (ru) 2018-03-30
DOP2013000216A (es) 2013-12-15
MY163004A (en) 2017-07-31
MX2013011423A (es) 2014-04-30
US20140336237A1 (en) 2014-11-13
US20120277284A1 (en) 2012-11-01
CN103562215B (zh) 2017-04-26
CA2831915A1 (en) 2012-10-04
CN103562215A (zh) 2014-02-05
SG193504A1 (en) 2013-10-30
CO6821885A2 (es) 2013-12-31
EA201792185A2 (ru) 2018-06-29
PE20142463A1 (es) 2015-01-22
EP3466960A2 (en) 2019-04-10
ZA201308153B (en) 2016-01-27
CY1121460T1 (el) 2020-05-29
EA201792185A3 (ru) 2018-10-31
NI201300101A (es) 2014-07-08
LT2697243T (lt) 2019-04-10
US20160348104A1 (en) 2016-12-01
EP2697243A4 (en) 2015-04-01
GT201300232A (es) 2015-02-11
WO2012135736A2 (en) 2012-10-04
ME03317B (me) 2019-10-20
JP2014511686A (ja) 2014-05-19
CN107012144A (zh) 2017-08-04
IL228569A (en) 2017-12-31
ES2709495T3 (es) 2019-04-16
NZ616036A (en) 2015-09-25
DK2697243T3 (en) 2019-02-11
EP2697243B1 (en) 2018-10-31
HRP20182169T1 (hr) 2019-04-19
BR112013024768B1 (pt) 2022-02-08
HUE042173T2 (hu) 2019-06-28
KR102050469B1 (ko) 2019-12-02
US20200385716A1 (en) 2020-12-10
CL2013002773A1 (es) 2014-04-04
WO2012135736A3 (en) 2012-12-06
AU2012236206B2 (en) 2015-09-17
AU2012236206C1 (en) 2018-03-08
EP2697243A2 (en) 2014-02-19
JP5943993B2 (ja) 2016-07-05

Similar Documents

Publication Publication Date Title
EA201391329A1 (ru) Модуляция экспрессии трансдуктора сигнала и активатора транскрипции 3 (stat3)
EA201390214A1 (ru) Гетероарилы и их применение
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
EA201490922A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
MA35660B1 (fr) Inhibiteurs de la protéine pak pour le traitement du syndrome de l'x fragile
MX362550B (es) Inhibidores ciclicos de glutaminasa.
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
EA201270149A1 (ru) Ингибиторы bace
IN2012DN03883A (ru)
BR112013014119A8 (pt) Novos moduladores e métodos de uso
ATE505191T1 (de) Ectoin zur behandlung von vascular leaks
BR112013021134A2 (pt) moduladores e métodos de uso
WO2012034116A3 (en) Small molecules as epigenetic modulators of lysine-specific demethylase 1 and methods of treating disorders
EA201391389A1 (ru) Кристаллы антител против склеростина и составы на их основе
EA201270100A1 (ru) Пиримидиноны в качестве ингибиторов pi3k
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
BR112013005116A2 (pt) moduladores e métodos de uso
BR112013004776A2 (pt) moduladores de proteína notum e métodos de uso
EP3715457A3 (en) Modulation of prekallikrein (pkk) expression
EA201201000A1 (ru) Способы лечения колоректального рака
EA201592238A1 (ru) Ингибиторы протеинкиназы pi3k, в частности ингибиторы pi3k дельта и/или гамма
EA201490688A1 (ru) 2-тиопиримидиноны
EA201490450A1 (ru) Новые ингибиторы ферментов
MX369349B (es) Metodos para hacer inhibidores de la proteina deacetilasa.
MX2013011490A (es) Derivados de piridopirazina y su uso.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU